close button

Jeremy Newman

Partner – Corporate, M&A and Private Equity; Capital Markets

Jeremy draws on his depth of experience working with and alongside stock exchanges and regulators in assisting clients reach positive outcomes in constantly evolving landscapes. He has a particular drive for understanding his clients’ businesses and how best to deliver commercial outcomes for them, as well as a passion for dealing with new and emerging industries. His outgoing manner is at the heart of his work and interactions with clients and his wider team.

Jeremy has extensive experience advising clients on a broad range of corporate, commercial and compliance matters, with a focus on listed entities and entities working towards a listing. He also provides practical and commercial advice in relation to the initial public offers, secondary raisings, ASX Listing Rules, JORC compliance, medtech and biotech reporting, spin-outs and backdoor listings.

In addition to his legal background, Jeremy has also worked in the Listings Compliance team at the ASX. His involvement in the development of ASX policy has given him valuable insights into both ASX and ASIC’s policy concerns.

Prior to joining Hamilton Locke, Jeremy worked for HWL Ebsworth Lawyers, Bellanhouse Lawyers and the ASX.

AREAS OF EXPERTISE

Equity Capital Markets; Corporate Advisory; Corporate Structuring; Corporate Governance; Energy and Resources; Mergers and Acquisitions

 

QUALIFICATIONS

  • Master of International Relations and Affairs – Instituto de Empresa (Spain)
  • Bachelor of Laws, Bachelor of Arts – Murdoch University
  • Company Directors Course, Australian Institute of Company Directors
  • Admitted to practice in Western Australia

 

SELECTED REPRESENTATIONS

  • Advised Argenica Therapeutics, Dynamic Drill and Blast Holdings, Osteopore, EMVision Medical Devices, Live Verdure, InteliCare Holdings, Emerald Clinics (Now Emyria), Green Technology Metals and Heavy Minerals on IPO and ASX Listing as well as ongoing compliance work.
  • Advised Metminco (now Los Cerros) on its off-market takeover of Andes Resources Ltd and various capital raisings.
  • Advised Canaccord Genuity and Morgans Corporate on various underwriting agreements. 
  • Advised industry trailblazers such as Little Green Pharma (medicinal cannabis producer) and Emerald Clinics (now Emyria) (data backed drug development and clinical care) on their successful in-principle applications for ASX listing.
  • Advised Ardea Resources on the spin out and subsequent IPO and listing of both Kalgoorlie Gold Mining and Godolphin Resources.
  • Advised Serpentine Technologies and Acacia Coal Limited on the backdoor listings of K-TIG and Sparc Technologies respectively.
  • Advised Suvo Strategic Minerals on its acquisition of the Pittong Kaolin Mine from Imerys Group.